|
SmithKline Beecham and Glaxo Wellcome are planning to divide their drug research operations into eight competing profit centres, in order to ensure that innovation is not lost when the two groups merge. 13-Nov-2000 SmithKline Beecham is to acquire Block Drug, the US toothpaste company, for £850m, in order to expand its dental care division. 09-Oct-2000 SmithKline Beecham has sold three pharmaceutical products in order to help secure approval for its merger with Glaxo Wellcome, with Famvir and Vectavir going to Novartis and Kytril to Roche. 01-Sep-2000 SmithKline Beecham is investing £6m in a new bottling centre for Lucozade and Ribena at its Forest of Dean factory. 13-Jun-2000 Glaxo Wellcome and SmithKline Beecham have dropped plans to combine their US headquarters onto a single site, and will instead operate from the two existing sites in Philadelphia and North Carolina. 09-Jun-2000 Glaxo Wellcome and SmithKline Beecham have announced plans to base their new corporate headquarters at SB's site in Brentford, while the pharmaceutical operating company will move to Stockley Park and seven other sites will close. 11-May-2000 Glaxo Wellcome and SmithKline Beecham have won approval from the European Commission for their merger, provided they dispose of products with EU sales of £50m. 09-May-2000 Scottish Power has won government approval to build a 45MW combined heat and power station at SmithKline Beecham's factory in Irvine, Ayrshire. 24-Feb-2000 Glaxo Wellcome is to merge with SmithKline Beecham to create a combined pharmaceuticals group with market capitalisation of £107bn, and the operational headquarters will be moved to the US. 18-Jan-2000 Glaxo Wellcome has resumed negotiations for a merger with SmithKline Beecham, which could lead to the creation of the world's largest pharmaceuticals group. 15-Jan-2000 SmithKline Beecham has awarded a £5m contract to Walter Lilly for the refurbishment of laboratories in Harlow, Essex. 08-Jan-2000 SmithKline Beecham has had its Avandia diabetes drug rejected by the European Agency for the Evaluation of Medicine, but will appeal against the decision. 22-Oct-1999 Skyepharma is to develop a controlled release version of the Requip treatment for Parkinson's disease, in a £5m alliance with SmithKline Beecham. 14-Sep-1999 SmithKline Beecham is to cut 240 jobs at its pharmaceuticals plant in Worthing, and some of the production will be moved to Irvine in Scotland where it will invest £17m. 09-Jul-1999 Goldshield is to increase its exports of pharmaceutical sales by acquiring the rights to 10 products from SmithKline Beecham at a cost of £17m. 08-Jul-1999 SmithKline Beecham is said to have started merger talks with Novartis of Switzerland, in order to create a £110bn pharmaceuticals group. 14-Jun-1999 SmithKline Beecham is to develop a new £240m headquarters in Brentford, which is expected to house 2,200 staff when completed in two years time. 11-Jun-1999 SmithKline Beecham has won US approval to market its Avandia diabetes drug, and will co-promote the product with Bristol-Myers Squibb. 27-May-1999 SmithKline Beecham has won US approval for its Avandia diabetes drug. 23-Apr-1999 SmithKline Beecham is abandoning the development of its potentially-important idoxifene drug as a treatment for osteoporosis due to concerns over side-effects. 21-Apr-1999 Skyepharma has won US approval for an oral controlled release version of SmithKline Beecham's anti-depressant Paxil. 19-Feb-1999 SmithKline Beecham is selling Diversified Pharmaceutical Services, the pharmacy benefit business, to Express Scripts of the US for £427m, and its US clinical labs to Quest Diagnostics for £625m. 10-Feb-1999 SmithKline Beecham is planning to rationalise its supply chain and reduce the number of manufacturing sites, which will result in the loss of about 3,000 jobs worldwide. 10-Feb-1999 SmithKline Beecham has won US approval for a vaccine against Lyme disease. 23-Dec-1998 SmithKline Beecham is acquiring joint commercial rights for a lymphoma treatment from Coulter Pharmaceutical of the US at a cost of up to £80m. 05-Dec-1998 SmithKline Beecham has applied for US FDA approval to market its new diabetes treatment Avandia. 01-Dec-1998 SmithKline Beecham is to invest £200m in the expansion of its drugs plant in Cork, Ireland, in order to meet rising demand for its Seroxat anti-depressant, and 320 jobs will be created. 21-Oct-1998 SmithKline Beecham has won UK approval to use its best-selling Seroxat drug to treat people who suffer from social anxiety disorder. 09-Oct-1998 SmithKline Beecham is to invest $50m in a new joint venture pharmaceuticals plant in north-eastern China, plus $25m in a plant in Shanghai. 08-Oct-1998 SmithKline Beecham is buying a 65% stake in Europharm, the Romanian pharmaceuticals group, for £18m, and has an option over the remaining shares. 28-Sep-1998 Alizyme has announced a licensing agreement with SmithKline Beecham for the development of a new treatment for irritable bowel syndrome. 23-Jul-1998 SmithKline Beecham is planning to sell its Bencard Allergy business to management for £20m. 22-Jun-1998 SmithKline Beecham is to restructure its UK pharmaceuticals business at Welwyn Garden City, which could result in a move to new offices in Brentford and the loss of 123 jobs. 05-Jun-1998 SmithKline Beecham has decided not to proceed with plans to sell a new migraine treatment that has been developed by Vanguard Medica, and Vanguard is now looking for another marketing partner for the drug. 14-May-1998 SmithKline Beecham has agreed a $200,000 contract with the Indian Institute of Chemical Technology for research into medicinal chemistry. 04-May-1998 SmithKline Beecham has expressed confidence in its future as an independent company following the recent collapse of merger talks with Glaxo Wellcome, and has outlined plans for new treatments for diabetes, osteoporosis, asthma, anxiety, and the narrowing of coronary arteries. 15-Apr-1998 Seton Healthcare is to buy SmithKline Beecham's Resolve cure for hangovers and indigestion for £4.75m, including the trademark, plant, machinery and stock. 26-Feb-1998 Glaxo Wellcome and SmithKline Beecham have called off their merger discussions having failed to agree on the management structure of the combined group. 24-Feb-1998 SmithKline Beecham and Glaxo Wellcome are planning to announce details of their £100bn merger next month. 18-Feb-1998 Glaxo Wellcome and SmithKline Beecham are planning a £100bn merger to create the largest pharmaceuticals company in the world, thereby putting an end to SmithKline's plans to merge with American Home Products. 31-Jan-1998 SmithKline Beecham has confirmed that it is in merger discussions with American Home Products to create the world's largest pharmaceuticals group with sales of about £16bn. 21-Jan-1998 SmithKline Beecham is discussing a tie-up with American Home Products, probably in consumer medicines. 17-Jan-1998 SmithKline Beecham has settled a patent dispute with Lek, which will allow the Slovenian drug company to sell a version of SmithKline's Augmentin antibiotic throughout Europe from 2000. 10-Jan-1998 SmithKline Beecham is linking up with MedImmune of the US to develop human papillomavirus vaccines for the prevention of genital warts and cervical cancer. 12-Dec-1997 SmithKline Beecham has won US approval to market Requip, the treatment for Parkinson's disease, which is expected to achieve worldwide sales of £200m a year. 24-Sep-1997 SmithKline Beecham is setting up a joint venture with Incyte of the US called Diadexus, which will develop diagnostic tests based on genes identified by SB's drug discovery work. 03-Sep-1997 SmithKline Beecham is taking a 10% stake in a new biotechnology company called Adprotech, and will spin off some of its non-core patents into the company. 08-Aug-1997 SmithKline Beecham has won the US marketing rights for Baycol, the cholesterol-lowering drug developed by Bayer. 23-Jul-1997 Sanofi Winthrop is to cut 130 jobs at its pharmaceutical plant in Fawdon, Newcastle, due to the loss of a contract with SmithKline Beecham. 18-Jul-1997 Holliday Chemical has acquired Laboratorios Julian de Mexico, the Mexican chemicals company, from SmithKline Beecham for £4.7m. 18-Jul-1997 SmithKline Beecham is stopping trials of a rheumatoid arthritis drug due to adverse side-effects on the immune system. 25-Jun-1997 SmithKline Beecham has won FDA approval for Coreg, its treatment for congestive heart failure, which will be marketed in collaboration with Boehringer Mannheim. 30-May-1997 SmithKline Beecham has won a contract to run the pathology laboratory at West Middlesex hospital and plans to win more contracts across the UK and north west Europe. 21-Mar-1997 SmithKline Beecham is setting up research alliances with Evotec BioSystems of Germany and Cadus Pharmaceutical of the US, in order to increase the rate of new drug discovery. 28-Feb-1997 SmithKline Beecham has agreed a £200m settlement with US regulators concerning allegations that its Pennsylvania laboratories has falsely claimed payments from Medicare, the state-funded health plan. 25-Feb-1997 Peptide Therapeutics has reached agreement with SmithKline Beecham for the marketing of its new allergy vaccine. 11-Feb-1997 SmithKline Beecham has won UK approval for ropinirole, the treatment for Parkinson's disease which will be sold under the ReQuip trade name. 09-Jul-1996 SmithKline Beecham is selling results of its gene research to Schering-Plough of the US and Synthelabo of France for $55m and $35m respectively. 03-Jul-1996 Glaxo Wellcome and SmithKline Beecham are to collaborate in the development of treatments for antibiotic-resistant germs. 07-Jun-1996 SmithKline Beecham has had a set-back in its plans for the Coreg heart drug, as advisers to the US FDA have voted not to recommend its approval. 04-May-1996 SmithKline Beecham is to restructure by cutting 400 jobs and closing 10% of its manufacturing sites, including a reduction in size at its Crawley plant, although it will increase the size of its plant in Worthing. 01-Mar-1996 SmithKline Beecham is making a £250m provision to cover two disputes in the US - one concerning antitrust pricing and the other for alleged false claims for payment from the Medicare and Medicaid health service schemes. 21-Feb-1996 SmithKline Beecham is merging its four service activities into one unit called Healthcare Services. 12-Jan-1996 SmithKline Beecham has acquired Abtei Pharma Vertreibs, the German consumer medicines concern, for £91m. 22-Dec-1995 Seton Healthcare has bought the Ralgex and Diocalm brands from SmithKline Beecham. 14-Dec-1995 Proteus International has awarded a patent licence to SmithKline Beecham for its NISV vaccine adjuvants technology. 02-Dec-1995 SmithKline Beecham is moving into healthcare management in South Africa, with the acquisition of Total Support Management. 27-Oct-1995 SmithKline Beecham is investing £39m in a R&D unit at its vaccines facility in Rixensart, Belgium. 24-Oct-1995 SmithKline Beecham plans to seek approval for 13 new drugs and 8 new vaccines over the next three years. 28-Sep-1995
|